The abstract is read at the publisher; the summary is JClub's.
IL-1β signaling in the tumor microenvironment is indispensable for immune checkpoint blockade responses and for intratumoral tumor-specific CD8+ T cell expansion, including Tcf1+ PD1+ progenitor exhausted T cells.
- Why it matters: ICB benefits only a subset of patients, and the contribution of non–T cells to ICB responsiveness is unclear, with IL-1β roles in antitumor immunity remaining controversial.
- What they did: The study engineered tumor-targeted inducible IL-1β-Fc–producing mesenchymal stromal cells (IL1βFc-EMSC) and tested how IL-1β signaling in dendritic cells via MyD88 affects type I IFN–dependent CD8+ T cell restimulation and activation.
- The result: IL1βFc-EMSC treatment expanded activated tumor-specific CD8+ T cells, reinvigorated tumor-infiltrating lymphocytes to overcome ICB resistance in advanced tumors, and was associated with a spatially organized IL-1β-cDC1-T pex axis linked to ICB responsiveness.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.